Antibody-drug conjugates (ADCs) are a new way to treat cancer by specifically targeting cancer cells, leading to fewer side effects compared to traditional chemotherapy. In simple terms, ADCs are like 'smart bombs' that find cancer cells and deliver a powerful drug to destroy them, while sparing nearby normal cells. ADCs can do that because the antibody component of the drug binds to specific receptors (proteins) that are only expressed on cancer cells. Some patients, however, don't respond well to this treatment due to certain challenges like loss of target receptors on cancer cells. With the support of the SCI Women’s Cancer Center Innovation Award, Bertozzi will introduce a new method to make ADCs work better by adding a 'smart receptor' to cancer cells. This receptor acts like a beacon guiding ADCs into the tumor cells, ensuring the drug reaches its intended cellular destination. This work aims to boost the effectiveness of ADCs, aiming to help more patients fight cancer effectively and safely.